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Abstract
We present a case of a 76-year-old diabetic patient on verapamil with undiagnosed renal failure
presenting with collapse and severe life threatening bradyarrhythmias. She responded well to
inotropic support and calcium supplementation.
Case presentation
A 76-year-old Anglo-Saxon Australian woman presented
15 minutes history of dizziness, lightheadedness, diaphor-
esis and collapse. According to the paramedics, her heart
rate was 30 per minute, blood pressure was not recordable
and heart sounds were feeble. She was given 1.2 mg
atropine and an adrenaline infusion was started at the rate
of 2 microgram/min. There was no history of chest pain,
palpitations, shortness of breath, loss of consciousness,
fall, seizures or injury. She was brought to the emergency
department with oxygen and adrenaline infusion. The
ECG rhythm strip prior to admission showed long pauses
extending more than 8 seconds, and junctional and
ventricular beats (Figure 1). On admission pulse was
50perminute,smallvolume,bloodpressure86/50mmHg,
respiratory rate 14 per minute and had oxygen saturation
of 98%. She was sweating and appeared sick. Systemic
examination was unremarkable except basal crepitations
posteriorly.
Further enquiry revealed that she had history of type II
diabetes for about 20 years. This was controlled with
regular treatment with gliclazide 30 mg OD. There was a
history of hypertension for which she was taking
verapamil 480 mg daily, and furosemide 20 mg OD.
Thyroid nodule was removed more than 20 years ago,
which was non cancerous and did not require any further
treatment. She had an episode of paroxysmal atrial
fibrillation 6 years ago, which did not recur. There was
no history of ischemic heart disease, peripheral vascular
disease or renal disease.
Differential diagnosis of ischemic episode, sick sinus
syndrome and verapamil toxicity were considered. Treat-
ment was continued with inotropes. Central line was
inserted and transvenous cardiac pacemaker was not
inserted as she was hemodynamically stable, though
kept ready. Presuming it to be an ischemic episode aspirin,
enoxaparin and atorvastatin was started.
Investigations revealed hemoglobin of 118 g/l, white cell
count of 18.3/nL, neutrophils of 14.7/nL. Cardiac enzymes
were normal (Trop T < 0.01). Serum creatinine was
200 µm/L (normal 55-110 µm/l), urea 18.8 mmol/l
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2.15-2.55 mmol/l), magnesium 1.12 mmol/l (normal
0.65-1.05mmol/l),phosphate1.57mmol/L(normal0.87-
1.45 mmol/l) and other electrolytes were normal. Arterial
blood gases showed pH 7.26, PO2 29 mmHg, and PCO2 –
57 mmHg. Random blood sugar was 19.4 mmol/L.
Thyroid function tests were normal. ECG showed a
junctional rhythm with a rate of 60/minute. Echocardio-
graphy showed left ventricular hypertrophy and normal
ejection fraction.
Inotropes increased the heart rate but with junctional
rhythm. Hypermagnesemia was reverted with 10 ml of
10% Calcium gluconate given intravenous over 10
minutes. Few minutes after the administration, the ECG
changed to atrial fibrillation with a ventricular rate of
96/min (Figure 2).
She was transferred to intensive care unit; adrenaline
infusion continued and later tapered off. Insulin (regular)
infusion was started for blood glucose control. The patient
was up and fit the next day. During the course of next 3
days, she went into rapid ventricular response with atrial
fibrillation and had to be controlled with intravenous
metoprolol. She remained in-patient for 4 days. Creatinine
dropped from 200 to 128 µmol/l, urea from 18.8 to
12.7 mmol/L and magnesium from 1.12 to 0.88 mmol/l.
She was discharged asymptomatic with rate controlled
atrial fibrillation.
Discussion
Verapamil is a commonly used calcium channel blocker
for management of hypertension, supraventricular tachy-
cardia, hypertrophic cardiomyopathy, angina pectoris,
mitral stenosis, migraine prophylaxis. It is also used to
treat hypertension associated with renal failure. Therapeu-
tic recommended doses are up to 480 mg/day [1]. Though
dose adjustment of verapamil has been suggested in renal
failure, it is not adequately stressed. It blocks rapid influx
of calcium into the cardiac myocytes of cardiac conduction
system and smooth muscle vasculature resulting in
decreased myocardial contractility, prolonged conduction
time, and vascular relaxation. Earlier reports have
suggested that slow release verapamil can cause acute
toxic effects (slow cardiac rhythms and hypotension) in
patients with chronic renal failure [2,3]. Death with
720 mg sustained release verapamil has also been reported
[4]. Though our patient was on therapeutic doses, she was
taking a dose in the higher range of the recommended.
The mechanism of cardiotoxicity in renal failure has been
suggested to be due to accumulation of verapamil or its
metabolites due to their reduced excretion [2]. However,
the role of magnesium in causing its toxicity has not been
studied.
Hypermagnesemia is commonly seen in renal failure [5].
Magnesium is an effective calcium channel blocker, which
when elevated, results in bradyarrhythmias [6]. Its toxicity
is linear and includes neuromuscular effects such as
depressed deep tendon reflexes, somnolescence, muscle
paralysis and quadriplegia. It causes hypocalcemia due to
parathyroid suppression. The effects on heart include
suppression of sinus node, delaying conduction through
the atrioventricular node and hypotension. Increased
levels can lead to prolongation of PR interval, increased
QRS duration and an increase in QT interval. In terminal
stages complete heart block and cardiac arrest can occur.
Since magnesium and verapamil both block the calcium
channels in the cardiac muscle, their actions may be
additive or synergistic. Hence, dose of verapamil bordering
the upper level of recommended may be harmful in
settings of hypermagnesemia. Conversely, lower than
reported toxic levels of magnesium may produce toxicity
in conjunction with verapamil. With no other likely
diagnosis and no evidence of acute cardiac insult, this
mechanism could have led to severe bradyarrhythmia in
our patient despite ‘therapeutic’ doses of verapamil and
mildly elevated magnesium levels. This is further sup-
ported by the temporal association of administration of
injection calcium gluconate and the heart rate picking up
within seconds in this patient. Though verapamil levels
were not tested in this patient, it could have given an
additional evidence for the diagnosis.
Figure 1. ECG prior to admission showing marked
bradyarrhythmia.
Figure 2. ECG after treatment demonstrating improvement
following administration of inotropes and intravenous calcium.
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verapamil should be given in lower doses. For these
patients, renal functions and magnesium levels should be
monitored regularly. This suggestion is particularly impor-
tant in hypertensive persons with diabetes who have a
greater propensity for development of renal failure. In the
event of development of cardiac toxicity in the form of
bradyarrhythmias, calcium gluconate infusion should be
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